论文部分内容阅读
为了提高对系统性硬皮病及皮肌炎的临床确诊率，通过ＥＮＡ抗原应用免疫印迹技术检测了１９例系统性硬皮病（ＳＳ）及２８例皮肌炎或多发性肌炎（ＤＭ／ＰＭ）患者抗Ｓｃｌ７０及抗Ｊｏ１抗体，并与系统性红斑狼疮（ＳＬＥ）、混合性结缔组织病（ＭＣＴＤ）共６２例及５０例健康人作了对照研究。结果表明：７０ＫＤ（抗Ｓｃｌ７０）多肽抗体是系统性硬皮病的特异性标记抗体，阳性率３１．６％；５５ＫＤ（抗Ｊｏ１）多肽抗体是皮肌炎的特异性标记抗体，阳性率４６．４％。ＳＬＥ、ＭＣＴＤ及健康人全部阴性，从而有助于对系统性硬皮病及皮肌炎的鉴别诊断
In order to improve the clinical diagnosis of systemic scleroderma and dermatomyositis, 19 cases of systemic scleroderma (SS) and 28 cases of dermatomyositis or polymyositis (DM / PM) patients with anti-Scl70 and anti-Jo 1 antibodies, and with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) a total of 62 cases and 50 healthy people were controlled. The results showed that: 70 KD (anti Scl 70) peptide antibody is a specific scleroderma labeled antibody, the positive rate was 31.6%; 55KD (anti-Jo 1) polypeptide antibody is a specific marker of dermatomyositis Antibody, the positive rate of 46.4%. SLE, MCTD and all the negative healthy people, which will help the differential diagnosis of systemic scleroderma and dermatomyositis